It is vital that recent high-profile concerns over funds with illiquid holdings do not discourage policymakers and regulators from addressing the patient capital - and equity gap - problem in the UK, writes Tom Hopkins
The modern industrial strategy launched back in 2017 has put innovation - and, in particular, university spin-out research and development (R&D) - at the forefront of positioning the UK in the wake of Brexit and beyond. And the government has done a good job redirecting capital to support its strategy - for instance, the rule changes regarding the Enterprise Investment Scheme (EIS) and venture capital trusts (VCTs) that were announced after the ‘patient capital review' in 2017 has resulted in more funds backing early-stage businesses. Even so, the policymakers understand the need for ...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
